e16441 Background: Pancreatic ductal adenocarcinoma is one of the most lethal malignancies with a 5-year survival rate under 5%. Locally advanced pancreatic ductal adenocarcinoma (LAP) represents 30-40% of cases at the diagnosis, with an overall survival around 15 months. Optimizing chemotherapy in LAP is still a huge challenge. A concomitant inhibition of epithelial mesenchymal transition (EMT) process may potentiate chemotherapy efficacy and decrease the development of resistances. Netrin-1 is upregulated in many metastatic cancers including 60% of pancreatic cancer and promotes tumor invasiveness and metastases development through EMT induction. NP137, a first-in-class anti-Netrin-1 monoclonal antibody, has shown in phase I study the ability to inhibit EMT, potentially overcoming resistance (Cassier et al., Nature, 2023). The goal of LAP-NET1 (NCT05546853) is to evaluate the safety and efficacy of the combination of modified FOLFIRINOX with anti-Netrin-1 targeting (NP137). Methods: LAP-NET1 is a phase 1b multicentric trial studying the combination of modified FOLFIRINOX with NP-137 every 2 weeks for 12 cycles in patients naive of systemic treatment with LAP according to National Comprehensive Cancer Network criteria. A safety lead-in phase will initially enroll 3-12 patients to confirm the recommended dose of NP137 (14 or 9 mg/kg) according to a 3+3 de-escalation protocol, followed by an expansion phase of 40 patients. The primary endpoint is the proportion of patients experiencing adverse events (AEs) of any grade and grade 3/4 AEs (CTCAE v 5.0) related to the experimental treatment at 6 months. Secondary endpoints are best overall objective response according to RECIST 1.1, 12-month progression-free survival (PFS-12m), 12-month overall survival (OS-12m), surgical resection rate, quality of life (EORTC QLQ-C30), time to deterioration and ancillary outcomes based on spatial transcriptomic and classic bulk RNA sequencing. Clinical trial information: NCT05546853 .
The influence of pelvic incidence (PI) on outcomes after hip arthroscopy for femoroacetabular impingement remains uncertain. This study evaluated whether PI was associated with one-year outcomes, pain, satisfaction, and willingness to repeat surgery. This retrospective multicentre cohort included 200 consecutive hips treated with hip arthroscopy for symptomatic femoroacetabular impingement and available standing EOS imaging. Hips were classified as low PI (≤ 40°), normal PI (40° < PI < 65°), or high PI (≥ 65°). Outcome analyses included 178 hips with available one-year Non-Arthritic Hip Score. Multivariable models adjusted for baseline outcome scores and prespecified covariates. Baseline characteristics did not differ significantly between PI groups. At one year, high PI was associated with lower Non-Arthritic Hip Score, modified Harris Hip Score, and International Hip Outcome Tool-12 scores, greater residual hip and low-back pain, lower satisfaction, and reduced willingness to repeat surgery. Improvement from baseline in Non-Arthritic Hip Score and International Hip Outcome Tool-12 did not differ significantly between groups. After adjustment, high PI remained associated with lower hip-specific scores, greater residual hip and low-back pain, lower global and activity-related satisfaction, lower odds of International Hip Outcome Tool-12 minimal clinically important difference achievement, and lower odds of answering “absolutely yes” to repeat surgery. Low PI was not significantly associated with adjusted outcomes. High PI was associated with inferior one-year postoperative status after hip arthroscopy for femoroacetabular impingement. However, most patients achieved clinically meaningful improvement, suggesting that high PI should guide counselling and risk stratification rather than contraindicate arthroscopy.
BACKGROUND:Perioperative FLOT (fluorouracil, oxaliplatin, and docetaxel) triplet chemotherapy is the standard of care for localised and resectable gastric and gastro-oesophageal junction adenocarcinoma. We aimed to compare a modified FLOT regimen (also known as TFOX) with FOLFOX as first-line treatment for patients with HER2-negative advanced gastric and gastro-oesophageal junction adenocarcinoma. METHODS:PRODIGE 51-FFCD-GASTFOX is an open-label, multicentre, randomised, phase 3 trial conducted at 96 medical centres in France. Eligible individuals were aged 18 years or older, had histologically confirmed, HER2-negative adenocarcinoma of the stomach or gastro-oesophageal junction that was locally advanced unresectable or metastatic and previously untreated, measurable disease per Response Evaluation Criteria in Solid Tumours, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients were randomly assigned (1:1), using the minimisation method, to receive FOLFOX (folinic acid 400 mg/m2, oxaliplatin 85 mg/m2, and 5-fluorouracil bolus 400 mg/m2 then 5-fluorouracil 2400 mg/m2 as a continuous 46 h infusion every 2 weeks) or TFOX (docetaxel 50 mg/m2, folinic acid 400 mg/m2, and oxaliplatin 85 mg/m2 then 5-fluorouracil 2400 mg/m2 as a continuous 46 h infusion every 2 weeks). Randomisation was stratified by centre, ECOG performance status, (neo)adjuvant chemotherapy or chemoradiotherapy, tumour stage, tumour location, and pathological histological subtype. The primary endpoint was progression-free survival (assessed in the intention-to-treat population), defined as time from randomisation to the first radiological or clinical progression (or both), or death due to any cause, whichever occurred first. Secondary endpoints included overall survival (defined as time from randomisation to death due to any cause) and objective response rate (defined as the proportion of patients with a best overall complete or partial response). Hazard ratio and 95% CIs were estimated using an unstratified Cox proportional hazards model. When the proportional hazards assumption was violated, the restricted mean survival time was used to estimate the treatment effect size. This study is registered with ClinicalTrials.gov, NCT03006432, and EudraCT, 2016-002331-16. FINDINGS:Between Dec 19, 2016, and Dec 26, 2022, 507 patients were randomly assigned (254 to the TFOX group and 253 to the FOLFOX group [intention-to-treat population]). The median age was 64·2 years (IQR 56·7-70·8), and 399 (79%) participants were male and 108 (21%) were female. At median follow-up of 42·8 months (25·8-49·9), the median progression-free survival was 7·59 months (95% CI 7·06-7·95) in the TFOX group versus 5·98 months (5·65-6·97) in the FOLFOX group. The assumption of proportional hazards was violated (p=0·013); therefore, the 12-month restricted mean progression-free survival was calculated: 7·52 months (7·06-7·97) in the TFOX group versus 6·62 months (6·16-7·09) in the FOLFOX group (p=0·0072). The median overall survival was 15·08 months (13·70-16·72) in the TFOX group versus 12·65 months (10·94-14·00) in the FOLFOX group (proportional hazards assumption was confirmed; HR 0·82 [0·68-0·99]; p=0·048) and the objective response rate was 62·3% (56·0-68·3) versus 53·4% (47·0-59·8; p=0·045). The most common grade 3 and 4 treatment-emergent adverse events were diarrhoea (37 [15%] in the TFOX group vs 18 [7%] in the FOLFOX group), peripheral neuropathy (80 [32%] vs 49 [20%]), neutropenia (67 [27%] vs 44 [18%]), and fatigue (40 [16%] vs 20 [8%]). Serious treatment-related adverse events occurred in 66 (27%) participants in the TFOX group and 33 (13%) in the FOLFOX group. There were two (<1%) treatment-related deaths in the TFOX group (one due to septic shock and one due to gastrointestinal perforation) and one (<1%) in the FOLFOX group (due to septic shock). INTERPRETATION:The modified FLOT/TFOX regimen significantly improved progression-free survival, overall survival, and objective response rate compared with FOLFOX in previously untreated patients with advanced HER2-negative gastric and gastro-oesophageal junction adenocarcinoma. The modified FLOT/TFOX regimen might represent a new first-line treatment option for patients eligible for this docetaxel triplet chemotherapy. FUNDING:Fédération Francophone de Cancérologie Digestive.
PURPOSE:Up to 20% of patients remain dissatisfied following total knee arthroplasty (TKA), often due to anterior knee pain (AKP) and other patellofemoral complications. Several studies highlighted risks of over- or under-stuffing within the patellofemoral compartment, yet there are no standardised methods for their assessment, and their effects on patient-reported outcome measures (PROMs) remain unclear. The aim of this review was to synthesise and critically appraise all published studies that investigated effects of over- and under-stuffing the anterior compartment on PROMs following primary TKA. METHODS:The protocol for this systematic review followed PRISMA guidelines was registered on PROSPERO (July 2024), before electronic searches by two readers (C.K. and V.G.) using Medline and Scopus. The authors included clinical studies published in English, reporting a quantifiable method to assess the anterior compartment in TKA, with clinical and/or radiographic outcomes. The authors excluded in vitro or ex vivo studies, reviews or editorials, studies on revision TKA and studies with follow-up <1 year. RESULTS:Searches returned 160 records, of which 14 met the eligibility criteria (10 retrospective and 4 prospective), representing 4404 knees in 3718 patients. The primary outcome was over-stuffing in five studies, which investigated its correlation with PROMs and/or AKP, while the primary outcome was under-stuffing in two studies. The PROMs reported were Western Ontario and McMaster Universities Osteoarthritis Index (eight studies), knee society score (six studies), knee injury and osteoarthritis outcome score (two studies), as well as Oxford knee score, forgotten joint score and Kujala scores (each one study). Only two studies used dynamic assessments, while 12 used static assessments. Only 3 of the 14 studies found significant effects of over-stuffing (by >5 mm) on PROMs. CONCLUSIONS:Changes in anterior offset, particularly over-stuffing, may cause patellofemoral complications. Although it would be ideal to restore the anterior compartment, small deviations do not affect clinical outcomes. A threshold of 5 mm could represent the 'safe zone' for change in anterior offset in patients undergoing TKA. LEVEL OF EVIDENCE:Level III.
Lateral ankle sprain (LAS) is the most common traumatic injury, with a high recurrence rate and chronic ankle instability (CAI) developing in ∼40% of cases. LAS leads to patho-mechanical, sensory-perceptual and motor-behavioral deficits. Poor management of the return-to-sport (RTS) is now considered a major cause of re-injury and development of CAI, particularly due to the lack of validated tests and the failure of existing ones to account for those central deficits. The first part of this topic aimed to clarify concepts of cognitive constructs and sensory reweighting and their association with CAI. We also aimed to identify objective RTS criteria and discuss their limits regarding their ability to encompass central impairments. Motor-cognitive deficits have been identified using computerized cognitive tasks and dual-task paradigms. More specifically, deficits in visual memory, processing speed or inhibitory control and attentional resource allocation have demonstrated reduced performance in CAI populations. In addition, altered sensory reweighting process towards visual input has also been observed. While objective criteria are crucial to prevent re-injury, current evaluations remain largely subjective and central impairments are unaccounted for in conventional RTS testing. The Ankle-GOTM score was recently developed to guide clinicians in decision making process. To date, it is the first validated score that could help to identify patients who will RTS at the same level, those at risk of recurrence and those who are more likely to become copers. Unfortunately, it does not target cognitive or sensory reweighting alterations, that are both relevant in sport to manage gameplay demands.